Suspension of trading
Biotest AG Stock Deutsche Boerse AG
Stocks
BIO3
DE0005227235
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.20 EUR | +1.34% |
|
+1.34% | +13.53% |
| 06-16 | Biotest GmbH & Co. KGaA announces Annual dividend, payable on July 24, 2026 | CI |
| 03-26 | Biotest GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 657M 757M 612M 563M 1.06B 71.96B 1.08B 7.22B 2.82B 35.97B 2.84B 2.78B 119B | P/E 2024 * |
-
| P/E 2025 | -17.7x |
|---|---|---|---|---|---|
| Enterprise Value | 1.4B 1.61B 1.3B 1.2B 2.27B 153B 2.29B 15.37B 6.01B 76.6B 6.05B 5.92B 254B | EV / Sales 2024 * |
-
| EV / Sales 2025 | 3.36x |
| Free-Float |
19.59% | Yield 2024 * |
-
| Yield 2025 | 0.13% |
| 1 week | +1.34% | ||
| 1 month | +1.34% | ||
| 3 months | +4.50% | ||
| 6 months | +16.15% | ||
| Current year | +13.53% |
| 1 week | 29.6 |  | 30.2 |
| 1 month | 29.6 | | 30.2 |
| 3 years | 23 | | 36.3 |
| 5 years | 19.85 | | 43.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jörg Schüttrumpf
CEO | Chief Executive Officer | 52 | 28/05/2025 |
Oliver Hein
CMP | Compliance Officer | - | 01/01/2017 |
Christian Polus
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 05/05/2022 | |
Dirk Schuck
BRD | Director/Board Member | 48 | 06/04/2022 |
David Ian Bell
BRD | Director/Board Member | 72 | 01/06/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.34% | +1.34% | +14.83% | -15.17% | 1.51B | |
| +0.19% | +9.42% | +33.09% | -0.75% | 75.96B | |
| +1.97% | -8.97% | +22.24% | +185.79% | 49.03B | |
| +3.72% | -4.71% | -8.40% | +20.60% | 47.88B | |
| +1.42% | +2.02% | -51.10% | -50.16% | 43.39B | |
| +3.29% | +1.38% | +57.68% | -22.49% | 30.8B | |
| +1.83% | -7.18% | +54.54% | +89.53% | 24.45B | |
| +3.36% | +2.12% | +106.19% | -47.32% | 22.75B | |
| +4.15% | +0.67% | -8.56% | +210.84% | 19.24B | |
| +0.46% | -7.19% | +59.71% | +117.00% | 15.87B | |
| Average | +2.30% | -0.84% | +28.02% | +48.79% | 36.6B | |
| Weighted average by Cap. | +2.05% | +0.79% | +22.11% | +42.83% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 726M 836M 677M 622M 1.18B 79.56B 1.19B 7.98B 3.12B 39.77B 3.14B 3.07B 132B | 649M 747M 605M 556M 1.05B 71.09B 1.06B 7.13B 2.79B 35.54B 2.81B 2.74B 118B |
| Net income | 26.4M 30.4M 24.61M 22.61M 42.77M 2.89B 43.23M 290M 113M 1.45B 114M 112M 4.79B | -70.7M -81.42M -65.92M -60.56M -115M -7.75B -116M -777M -304M -3.87B -306M -299M -12.83B |
| Net Debt | 552M 636M 515M 473M 895M 60.5B 904M 6.07B 2.37B 30.25B 2.39B 2.34B 100B | 742M 854M 692M 635M 1.2B 81.26B 1.21B 8.15B 3.19B 40.62B 3.21B 3.14B 135B |
Employees
-
Sector
Pharmaceuticals
Net sales - Rate of surprise
- Stock Market
- Stocks
- BIO0 Stock
- BIO3 Stock
Select your edition
All financial news and data tailored to specific country editions
